RBC
RARE icon

Roble Belko & Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Roble Belko & Company’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-44
Closed -$3K – 339
2017
Q1 		$3K Hold
44
– – ﹤0.01% 292
2016
Q4 		$3K Buy
+44
New +$3.12K ﹤0.01% 311

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Roble Belko & Company's RARE Position: Q2 2017 in Review

Roble Belko & Company sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2017, closing a stake of 44 shares — an estimated $3K sold.

Roble Belko & Company first reported a position in RARE in Q4 2016 and held it in 2 quarters. The position peaked at $3K in Q1 2017. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2017.

  • Roble Belko & Company reported no remaining Ultragenyx Pharmaceutical position as of Q2 2017 after selling out during the quarter.
  • Roble Belko & Company sold 44 Ultragenyx Pharmaceutical shares in Q2 2017, an estimated $3K.
  • Roble Belko & Company first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 2 quarters.
  • Roble Belko & Company's Ultragenyx Pharmaceutical position peaked at $3K in Q1 2017.
  • 158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2017.

Based on Roble Belko & Company's 13F filing for Q2 2017, filed 11 Aug 2017.